Barr Laboratories Inc., Galen deal

BRL signed a letter of intent to acquire from GAL exclusive rights in the U.S. and Canada to Loestrin and Loestrin FE oral contraceptives. The companies also proposed to settle their pending litigation related to GAL's femhrt hormone replacement therapy and Estrostep oral contraceptive. The settlement would allow BRL to launch generic versions of the products six months prior to patent expiration. In exchange, BRL would make a one-time $45 million payment to GAL. ...